US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
A woman died of total organ failure after she developed profound electrolyte abnormalities from vomiting while taking Ozempic ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Hosted on MSN15h
Lighter but weaker? The hidden costs of Ozempic and weight-loss drugs for endurance athletesOzempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
USA TODAY on MSN13d
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiationsThe Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
Posts about unexpected pregnancies while using drugs such as Ozempic for weight loss are trending on social media. Does any scientific evidence back this up? Sangeetha Nadarajah reports Amid the ...
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback